Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Nov 24, 2026; 17(11): 126582
Published online Nov 24, 2026. doi: 10.5306/wjco.126582
Published online Nov 24, 2026. doi: 10.5306/wjco.126582
Machine learning and logistic regression for ascertainable three-year recurrence status after soft tissue sarcoma surgery
Zhang-Fu Li, Bai-Cheng Yang, Shi-Qing Liu, Sheng-Ji Yu, Department of Orthopaedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Yi-Bo Liu, Qing Zhang, Department of Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China
Co-first authors: Zhang-Fu Li and Bai-Cheng Yang.
Co-corresponding authors: Qing Zhang and Sheng-Ji Yu.
Author contributions: Li ZF and Yang BC contributed to the study design, curation of the development cohort, the statistical performance and machine-learning analysis, and the manuscript drafting; Liu YB contributed to the collection, verification, and interpretation of the second-institution cohort; Liu SQ contributed to the data acquisition, variable definition, and outcome ascertainment; Liu SQ and Zhang Q contributed to the clinical interpretation and revision; Li ZF and Yang BC contributed to the preparation of the figures and tables; Zhang Q contributed to the supervision of the second-institution cohort; Yu SJ contributed to the supervision of the study, the methodological and clinical guidance. Zhang Q and Yu SJ contributed equally to this work as co-corresponding authors. Li ZF and Yang BC contributed equally to this work as co-first authors.
AI contribution statement: OpenAI Codex was used during manuscript revision for code assistance, language editing, and drafting support. All analyses, outputs, citations, and text were reviewed and verified by the authors, who take full responsibility for the final manuscript.
Supported by the National Natural Science Foundation of China, No. 82272964; and the National High Level Hospital Clinical Research Funding, No. 80102022625.
Institutional review board statement: This retrospective study used the approved multicenter soft tissue sarcoma database and was approved by the Independent Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. NCC2020C-341. The multicenter database framework covered de-identified data contributed by both participating institutions, including Beijing Jishuitan Hospital. The study was conducted in accordance with the Declaration of Helsinki.
Informed consent statement: The requirement for informed consent was waived by the approving ethics committee because this retrospective study used de-identified data.
Conflict-of-interest statement: The authors declare no conflicts of interest related to this work.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Patient-level data are not publicly available because of ethical and privacy restrictions. De-identified data may be available from the corresponding authors on reasonable request, subject to institutional ethics and data-protection approval. A submission-stage reproducibility supplement contains the analysis protocol, configuration registry, aggregate internal and second-institution results, input schema, lock files, software versions, non-identifiable calculator materials, and revision sensitivity outputs. Patient-level predictions and fold assignments are available only under controlled institutional approval.
Corresponding author: Sheng-Ji Yu, Professor, Department of Orthopaedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. zlyygk@163.com
Received: August 10, 2026
Revised: September 24, 2026
Accepted: November 2, 2026
Published online: November 24, 2026
Processing time: 101 Days and 18.1 Hours
Revised: September 24, 2026
Accepted: November 2, 2026
Published online: November 24, 2026
Processing time: 101 Days and 18.1 Hours
Core Tip
Core Tip: We compared 243 configurations across 14 base-model families plus three prespecified ensembles by repeated nested cross-validation. The selected CatBoost model was frozen and applied without recalibration in a protocol-frozen second-institution re-evaluation. CatBoost retained an area under the receiver operating characteristic curve of 0.8050 but did not demonstrate incremental performance over either a six-variable or full 12-variable logistic model; this was not an equivalence or non-inferiority analysis. The browser interface is provided for reproducibility and independent evaluation, not for clinical decision-making.